A Phase 3 interventional study of V503 and Placebo to V503 in Cervical Cancers, Vulvar Cancers and Vaginal Cancers, sponsored by Merck Sharp & Dohme LLC. Completed. Open to female participants aged 12 Years to 26 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-11-27.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Uterine Cervical Neoplasms — 6 open to participants now, 8 under way, 3 of them phase 3. Human Papillomavirus Recombinant Vaccine nonavalent · Uterine Cervical Neoplasms.
Among the 14 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Uterine Cervical Neoplasms, this one is the 10th largest by enrollment, is the only one that started in 2010, is one of 9 in phase 3, and was the 2nd registered.
2,368 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.
Browse Uterine Cervical Neoplasms studies →6 of the 14 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Uterine Cervical Neoplasms are open now, in 5 countries. Recruiting first, the newest first:
Shanghai Bovax Biotechnology Co., Ltd. · Sites in China
Ages 9–45 · Women only · Healthy volunteers
Miriam Elfström · Sites in Sweden
Ages 22–27 · Women only
Institut d'Investigació Biomèdica de Bellvitge · Sites in Sierra Leone
Ages 18–29 · Women only
National Institute of Hygiene and Epidemiology, Vietnam · Sites in Australia, Vietnam
Ages 18–26 · Women only · Healthy volunteers
Rwanda Biomedical Centre
Ages 23–29 · Women only · Healthy volunteers
By country, each count listing its studies:
Human Papillomavirus Recombinant Vaccine nonavalent: first FDA approval 2014 (Gardasil 9). What it is approved for, and how studies give it, is on its page →
Of the 474 Uterine Cervical Neoplasms studies recruiting now, 244 (51%) set no upper age limit and 190 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.
This study: 12 Years to 26 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 1 started in 2010.
This study's enrollment of 924 is above the median of 100 across 1,739 interventional studies indexed under Uterine Cervical Neoplasms.
Median enrollment 1,206 across the 14 interventional studies. Of the 6 that completed or were terminated, 5 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 14 have an industry lead sponsor. The 9 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
31 studies in Uterine Cervical Neoplasms by Merck & Co., Inc: 3 open now, 6 under way, 2 of them phase 3. Of 24 finished, 17 (71%) have results posted.
Among the 31 studies in Uterine Cervical Neoplasms by Merck & Co., Inc, this one is the 13th largest by enrollment of the 29 interventional ones that give a count, is one of 2 that started in 2010, is one of 16 in phase 3, and was the 13th registered.
Merck & Co., Inc’s Uterine Cervical Neoplasms studies by the year they started, since 2001.
2 of the studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Uterine Cervical Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06411938Indiana UniversityA Cervical Cancer Prevention Program in Kenya | 2026-12-31 |
| NCT07303751Institut d'Investigació Biomèdica de BellvitgeStudy Assessing Reduced HPV Infectivity and Transmission in HPV-Positive Women Following Vaccination With 9vHPV | 2027-02-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 14 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Uterine Cervical Neoplasms, from their registry updates:
Among Merck & Co., Inc’s 31 in Uterine Cervical Neoplasms:
This tab as a report to print or save as PDF → With an account.
This study will evaluate whether V503 (9vHPV vaccine), is well tolerated in girls and women between 12 and 26 years old who have previously been vaccinated with GARDASIL™. Participants will receive vaccination with 9vHPV vaccine or placebo on Day 1, Month 2, and Month 6 of the Base Study. Participants who receive placebo in the Base Study will be eligible to receive vaccination with 9vHPV vaccine on Day 1, Month 2, and Month 6 of the Extension Study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants Age 12 to 15 Years:
Participants Age 16 to 26 Years:
Exclusion Criteria:
All participants:
Participants Age 16 to 26 Only:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blinded 9vHPV vaccine (V503) 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6 of the Base Study. Participants will not continue to the Extension Study.
Biological: V503
Blinded 0.5 mL intramuscular injection of saline placebo at Day 1, Month 2, and Month 6 of the Base Study. After completion of the Base Study, participants will be eligible to receive open-label 9vHPV 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6 of the Extension Study.
Biological: V503 · Biological: Placebo to V503
V503 (9vHPV) vaccine given as a 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6 of the Base Study or the Study Extension
Placebo to V503 (saline) given as a 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6 of the Base Study
Percentage of Participants Who Experience an Injection-site Adverse Event (AE) - Base Study
An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE. The percentage of participants who reported an AE that was associated with the injection site such as redness, swelling, and pain/tenderness/soreness was summarized.
Time frame: up to 5 days after any vaccination - Base Study
Percentage of Participants With Body Temperature ≥100.0°F (≥37.8ºC) - Base Study
Participants collected their oral body temperature in the evening of their vaccination day and at the same time each day thereafter for 4 days. The maximum body temperature obtained within 5 days of any of the 3 vaccinations was recorded.
Time frame: up to 5 days after any vaccination - Base Study
Percentage of Participants Who Experience a Systemic AE - Base Study
An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE. Systemic AEs were those not categorized as injection-site AEs.
Time frame: up to 14 days after any vaccination - Base Study
Percentage of Participants Who Experience a Serious Adverse Event (SAE) Within 15 Days of Any Vaccination - Base Study
An SAE is one that results in death, disability/incapacity, or hospitalization or is life threatening, a congenital anomaly or birth defect, cancer, an overdose, or otherwise jeopardizes the participant and may require medical intervention.
Time frame: up to 14 days after any vaccination - Base Study
Percentage of Participants Who Experience a Vaccine-related SAE Any Time During Study- Base Study
An SAE is one that results in death, disability/incapacity, or hospitalization or is life threatening, a congenital anomaly or birth defect, cancer, an overdose, or otherwise jeopardizes the participant and may require medical intervention. An SAE that is judged by the Investigator to be "definitely related," "probably related," or "possibly related" is defined as a vaccine-related SAE.
Time frame: Up to 7 months - Base Study
Percentage of Participants Who Experience a Severe Injection-site AE - Base Study
An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE. Participants were instructed to estimate the severity of AEs such as pain at injection site as mild (awareness of symptom, but easily tolerated), moderate (discomfort enough to cause interference with usual activities), or severe (incapacitating with inability to work or do usual activity). Additionally, participants were instructed to measure any swelling and/or erythema at its greatest width. Swelling or erythema with diameter \>2 inches (\>5 cm) was recorded as severe. All AEs associated with the injection site and reported as severe were summarized.
Time frame: up to 5 days after any vaccination - Base Study
Percentage of Participants Who Seroconvert to Each of the HPV Types Contained in the Vaccine - Base Study
Serum antibody titers for HPV virus-like particles (VLPs), Types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined 4 weeks post-vaccination 3 using competitive luminex immunoassay (cLIA). The serostatus cutoffs (milli Merck U/mL) for HPV types were as follows: HPV Type 6: ≥30, HPV Type 11: ≥16; HPV Type 16: ≥20, HPV Type 18: ≥24, HPV Type 31: ≥10, HPV Type 33: ≥8, HPV Type 45: ≥8, HPV Type 52: ≥8, and HPV Type 58: ≥8.
Time frame: 4 weeks post-vaccination 3 (Month 7; End of Base Study)
Percentage of Participants Who Experience an SAE- Extension Study
An SAE is one that results in death, disability/incapacity, or hospitalization or is life threatening, a congenital anomaly or birth defect, cancer, an overdose, or otherwise jeopardizes the participant and may require medical intervention.
Time frame: up to Month 7 - Extension Study
| Milestone | 9vHPV Vaccine - Base Study | Placebo - Base Study | 9vHPV Vaccine - Extension Study |
|---|---|---|---|
| Started | 618 | 306 | 0 |
| Vaccination 1 | 615 | 306 | 0 |
| Vaccination 2 | 604 | 304 | 0 |
| Vaccination 3 | 597 | 300 | 0 |
| Completed | 596 | 300 | 0 |
| Not completed | 22 | 6 | 0 |
| Withdrew: Adverse event | 3 | 0 | 0 |
| Withdrew: Lost to follow-up | 4 | 1 | 0 |
| Withdrew: Protocol violation | 3 | 1 | 0 |
| Withdrew: Withdrawal by subject | 12 | 4 | 0 |
| Milestone | 9vHPV Vaccine - Base Study | Placebo - Base Study | 9vHPV Vaccine - Extension Study |
|---|---|---|---|
| Started | 0 | 0 | 102 |
| Vaccination 4 | 0 | 0 | 102 |
| Vaccination 5 | 0 | 0 | 99 |
| Vaccination 6 | 0 | 0 | 95 |
| Completed | 0 | 0 | 96 |
| Not completed | 0 | 0 | 6 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 5 |
An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE. The percentage of participants who reported an AE that was associated with the injection site such as redness, swelling, and pain/tenderness/soreness was summarized.
| Percentage of Participants | 9vHPV Vaccine - Base Study | Placebo - Base Study |
|---|---|---|
| Percentage of Participants Who Experience an Injection-site Adverse Event (AE) - Base Study | 91.1 | 43.9 |
Participants collected their oral body temperature in the evening of their vaccination day and at the same time each day thereafter for 4 days. The maximum body temperature obtained within 5 days of any of the 3 vaccinations was recorded.
| Percentage of Participants | 9vHPV Vaccine - Base Study | Placebo - Base Study |
|---|---|---|
| Percentage of Participants With Body Temperature ≥100.0°F (≥37.8ºC) - Base Study | 6.5 | 3.0 |
An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE. Systemic AEs were those not categorized as injection-site AEs.
| Percentage of Participants | 9vHPV Vaccine - Base Study | Placebo - Base Study |
|---|---|---|
| Percentage of Participants Who Experience a Systemic AE - Base Study | 59.7 | 55.7 |
An SAE is one that results in death, disability/incapacity, or hospitalization or is life threatening, a congenital anomaly or birth defect, cancer, an overdose, or otherwise jeopardizes the participant and may require medical intervention.
| Percentage of Participants | 9vHPV Vaccine - Base Study | Placebo - Base Study |
|---|---|---|
| Percentage of Participants Who Experience a Serious Adverse Event (SAE) Within 15 Days of Any Vaccination - Base Study | 0.3 | 0.3 |
An SAE is one that results in death, disability/incapacity, or hospitalization or is life threatening, a congenital anomaly or birth defect, cancer, an overdose, or otherwise jeopardizes the participant and may require medical intervention. An SAE that is judged by the Investigator to be "definitely related," "probably related," or "possibly related" is defined as a vaccine-related SAE.
| Percentage of Participants | 9vHPV Vaccine - Base Study | Placebo - Base Study |
|---|---|---|
| Percentage of Participants Who Experience a Vaccine-related SAE Any Time During Study- Base Study | 0.2 | 0.3 |
An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE. Participants were instructed to estimate the severity of AEs such as pain at injection site as mild (awareness of symptom, but easily tolerated), moderate (discomfort enough to cause interference with usual activities), or severe (incapacitating with inability to work or do usual activity). Additionally, participants were instructed to measure any swelling and/or erythema at its greatest width. Swelling or erythema with diameter \>2 inches (\>5 cm) was recorded as severe. All AEs associated with the injection site and reported as severe were summarized.
| Percentage of Participants | 9vHPV Vaccine - Base Study | Placebo - Base Study |
|---|---|---|
| Percentage of Participants Who Experience a Severe Injection-site AE - Base Study | 11.2 | 1.0 |
Serum antibody titers for HPV virus-like particles (VLPs), Types 6, 11, 16, 18, 31, 33, 45, 52 and 58 were determined 4 weeks post-vaccination 3 using competitive luminex immunoassay (cLIA). The serostatus cutoffs (milli Merck U/mL) for HPV types were as follows: HPV Type 6: ≥30, HPV Type 11: ≥16; HPV Type 16: ≥20, HPV Type 18: ≥24, HPV Type 31: ≥10, HPV Type 33: ≥8, HPV Type 45: ≥8, HPV Type 52: ≥8, and HPV Type 58: ≥8.
| Percentage of Participants | 9vHPV Vaccine - Base Study | Placebo - Base Study |
|---|---|---|
| Anti-HPV 6 (n=511; n=251) | 100.0 (99.3 to 100.0) | 100.0 (98.5 to 100.0) |
| Anti-HPV 11 (n=515; n=261) | 100.0 (99.3 to 100.0) | 99.6 (97.9 to 100.0) |
| Anti-HPV 16 (n=515; n=261) | 100.0 (99.3 to 100.0) | 100.0 (98.6 to 100.0) |
| Anti-HPV 18 (n=515; n=261) | 100.0 (99.3 to 100.0) | 85.4 (80.6 to 89.5) |
| Anti-HPV 31 (n=515; n=261) | 99.8 (98.9 to 100.0) | 23.8 (18.7 to 29.4) |
| Anti-HPV 33 (n=515; n=261) | 99.8 (98.9 to 100.0) | 8.0 (5.0 to 12.0) |
| Anti-HPV 45 (n=515; n=261) | 98.3 (96.7 to 99.2) | 3.4 (1.6 to 6.4) |
| Anti-HPV 52 (n=515; n=261) | 99.6 (98.6 to 100.0) | 3.8 (1.9 to 6.9) |
| Anti-HPV 58 (n=515; n=261) | 99.8 (98.9 to 100.0) | 9.2 (6.0 to 13.4) |
An SAE is one that results in death, disability/incapacity, or hospitalization or is life threatening, a congenital anomaly or birth defect, cancer, an overdose, or otherwise jeopardizes the participant and may require medical intervention.
| Percentage of Participants | 9vHPV Vaccine - Extension Study |
|---|---|
| Percentage of Participants Who Experience an SAE- Extension Study | 2.0 |
Collected over Up to 5 days after any vaccination (Non-serious injection site AEs); up to 15 days after any vaccination (Non-serious systemic AEs) and up to 7 months (Serious AEs) - Base Study and Extension Study. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 9vHPV Vaccine - Base Study | — | 3/608 (0.5%) | 566/608 (93.1%) |
| Placebo - Base Study | — | 3/305 (1%) | 197/305 (64.6%) |
| 9vHPV Vaccine - Extension Study | — | 2/99 (2%) | 0/99 (0%) |
| Event | 9vHPV Vaccine - Base Study | Placebo - Base Study | 9vHPV Vaccine - Extension Study |
|---|---|---|---|
| Abdominal painGastrointestinal disorders | 0/608 | 0/305 | 1/99 |
| DiarrhoeaGastrointestinal disorders | 0/608 | 0/305 | 1/99 |
| Lumbar vertebral fractureInjury, poisoning and procedural complications | 0/608 | 1/305 | 0/99 |
| Thoracic vertebral fractureInjury, poisoning and procedural complications | 0/608 | 1/305 | 0/99 |
| MigraineNervous system disorders | 0/608 | 1/305 | 0/99 |
| Abortion inducedSurgical and medical procedures | 0/608 | 1/305 | 0/99 |
| AppendicitisInfections and infestations | 1/608 | 0/305 | 0/99 |
| TonsillitisInfections and infestations | 1/608 | 0/305 | 0/99 |
| SyncopeNervous system disorders | 1/608 | 0/305 | 0/99 |
| Event | 9vHPV Vaccine - Base Study | Placebo - Base Study | 9vHPV Vaccine - Extension Study |
|---|---|---|---|
| Injection site painGeneral disorders | 549/608 | 117/305 | 0/99 |
| Injection site swellingGeneral disorders | 298/608 | 18/305 | 0/99 |
| Injection site erythemaGeneral disorders | 258/608 | 26/305 | 0/99 |
| HeadacheNervous system disorders | 190/608 | 81/305 | 0/99 |
| NauseaGastrointestinal disorders | 52/608 | 12/305 | 0/99 |
| Injection site pruritusGeneral disorders | 48/608 | 4/305 | 0/99 |
| NasopharyngitisInfections and infestations | 47/608 | 19/305 | 0/99 |
| PyrexiaGeneral disorders | 42/608 | 10/305 | 0/99 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 40/608 | 12/305 | 0/99 |
| DizzinessNervous system disorders | 31/608 | 6/305 | 0/99 |
| Age, Customized(Participants) | 9vHPV Vaccine - Base Study | Placebo - Base Study | Total |
|---|---|---|---|
| 12 to 15 years | 122 | 60 | 182 |
| 16 to 26 years | 496 | 246 | 742 |
| Sex: Female, Male(Participants) | 9vHPV Vaccine - Base Study | Placebo - Base Study | Total |
|---|---|---|---|
| Female | 618 | 306 | 924 |
| Male | 0 | 0 | 0 |
No study locations are listed for this record.
Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Feb 2010 to primary completion in Jun 2011, 15 months.
Results were first posted in Dec 2014, 3 years 6 months after primary completion.
Of 46 industry-sponsored phase 3 interventional studies under Uterine Cervical Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 55. This study's 15 months is below that.
Counting every sponsor, half of 99 studies reached it within 55 months; a quarter within 24 and three quarters within 80.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Human Papillomavirus Recombinant Vaccine nonavalent